Jain Rita 4

What Happened
Rita Jain, a director of Avalo Therapeutics (AVTX), was granted derivative securities covering 1,080 shares on June 30, 2026. The grant has an exercise/strike price of $15.04 per share (1,080 × $15.04 = $16,243.20) and is reported as an acquisition of a derivative (award/grant), not a cash purchase or sale.

Key Details

• Transaction date: June 30, 2026; Form 4 filed: July 2, 2026.
• Grant type: Derivative award (options) for 1,080 shares, exercise price $15.04. Aggregate exercise cost shown as $16,243 (rounded in filing).
• Vesting: Footnote F1 states the options were granted on June 30, 2026 and are 100% vested (immediately exercisable).
• Shares owned after transaction: not specified in the filing.
• Filing timeliness: filing date is shown; the filing does not indicate a late-filing flag in the information provided here.

Context This report documents an option award (derivative grant). Options are a right to buy shares at the stated strike price; because these are fully vested, Jain can exercise them immediately if she chooses, which would convert the derivative into common shares and require payment of the exercise price. An award is not the same as an open-market purchase or sale and does not itself create immediate marketable shares unless exercised.